An open science pathway for drug marketing authorization—Registered drug approval

医学 临床试验 销售授权 批准的药物 家庭医学 临床研究 替代医学 药品 药理学 生物信息学 生物 病理
作者
Florian Naudet,Maximilian Siebert,Rémy Boussageon,Ioana A. Cristea,Erick H. Turner
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:18 (8): e1003726-e1003726 被引量:49
标识
DOI:10.1371/journal.pmed.1003726
摘要

ackgroundBefore drug approval, health authorities like the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) evaluate findings from the relevant clinical trials to assess the balance between clinical benefit and safety.When requesting marketing authorization for their drug products, pharmaceutical companies are allowed to choose the indication, design the trials, and choose assessments.In the US, pharmaceutical companies and drug manufacturers must submit full trial protocols to the FDA before those trials can begin.In Europe, companies can, at their discretion, obtain prior scientific advice from the EMA.This consultative process between sponsor and regulator is not fit for purpose, as there is, in practice, no clear a priori consensus on the exact criteria that will be applied to adjudicate success.Although the FDA lays out a set of a priori rules, all too often, it later bends those rules post hoc.For instance, for esketamine, for treatment of resistant depression, the FDA decided post hoc that a maintenance trial could substitute for a second positive short-term trial [1].OAU : Pleaseche ther examples include nalmefene for alcohol use disorder (approved by the EMA), which was based on a post hoc subgroup analysis of the pivotal trials [2], or eteplirsen for muscular dystrophy (approved by the FDA) despite a lack of clinical evidence [3].Even the initial standards agreed upon between the sponsor and regulator can be too lax.Too often, trials ask the wrong question: Trials may explore superiority over an inappropriately weak comparator such as placebo when superiority versus an already approved active comparator would be more clinically relevant [4].Trials can also be underpowered [4], focus on surrogate markers, or omit clinically relevant outcomes [5].Moreover, the regulator is laissez-faire with respect to trial publication in journal articles, allowing the sponsor to freely choose which findings to include and how to frame them, often diverging starkly from the

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
huhuiya完成签到,获得积分10
1秒前
坚定的连虎完成签到,获得积分10
1秒前
2秒前
2秒前
清风完成签到,获得积分10
2秒前
fj完成签到,获得积分10
2秒前
fogsea发布了新的文献求助10
2秒前
goodbuhui完成签到,获得积分10
3秒前
3秒前
灶鲜森发布了新的文献求助10
3秒前
勤恳夏旋发布了新的文献求助10
3秒前
蓝精灵完成签到 ,获得积分10
4秒前
猫小咪发布了新的文献求助10
4秒前
天天快乐的应助被七月晴采纳,获得10
5秒前
huhuiya发布了新的文献求助10
5秒前
zxd发布了新的文献求助10
5秒前
动听的秋白完成签到 ,获得积分10
5秒前
迷魂不得完成签到,获得积分10
5秒前
水煮电吹风的应助被时途采纳,获得10
5秒前
秒文献是一种天赋完成签到 ,获得积分10
6秒前
2577完成签到 ,获得积分10
6秒前
王献杰完成签到,获得积分10
7秒前
杰杰小杰发布了新的文献求助10
7秒前
阿符家的骡完成签到,获得积分10
7秒前
ponysmile完成签到,获得积分10
7秒前
莫生发布了新的文献求助10
7秒前
白色大鸟完成签到,获得积分10
8秒前
安静又夏完成签到,获得积分10
8秒前
8秒前
qiyue完成签到 ,获得积分10
8秒前
山海完成签到,获得积分10
8秒前
hooray完成签到,获得积分10
8秒前
张小完成签到,获得积分10
9秒前
wtz499078677完成签到,获得积分10
9秒前
时尚的从凝完成签到,获得积分10
9秒前
Nike发布了新的文献求助30
9秒前
张晓芮完成签到 ,获得积分10
9秒前
9秒前
大海之滨完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039